The ExoDx Prostate Test is a simple, non-invasive urine test that can help you and your doctor determine the need for an initial prostate biopsy or repeat biopsy due to a prior negative biopsy.

The ExoDx Prostate Test is unique because it provides an additional data point not obtained through the general workup – it offers exclusive information that is not influenced by DRE, family history, PSA or other clinical information.

If you’re visiting your doctor today, ask about the ExoDx Prostate Test.

Why the ExoDx Prostate Test?

☑ Helps inform if initial or repeat prostate biopsy is warranted
☑ Simple urine test can be collected any time of day
☑ Available at your doctor’s office or through our At-Home Collection Kit
☑ NO Digital Rectal Exam (DRE) required
☑ NO Blood Test

What does the test score mean?

<table>
<thead>
<tr>
<th>EPI below cut point:</th>
<th>EPI above cut point:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low risk or benign</td>
<td>Higher risk</td>
</tr>
</tbody>
</table>

Clinical decision:
- Potentially avoid biopsy, continued monitoring
- Proceed to biopsy

Cut point 15.6

Now available to Veterans as an At-Home Collection Kit

Doctor trusted. Clinically validated.

The ExoDx™ Prostate Test (EPI) provides actionable information that aids the prostate biopsy decision for men in the ‘gray zone’ of 2-10 ng/mL and is not dependent on PSA or other clinical risk factors.

When there is uncertainty about proceeding with a biopsy, The EPI Test may be a solution.

Clinical studies show The EPI Test may help avoid unnecessary biopsies in patients with PSA levels in the gray zone.

Watch how it works: [Getting Started with the ExoDx Prostate Test](#)
Take charge of your prostate health today

Prostate cancer is the second most common cancer in men.

Incidence among U.S. veterans is higher than the general population

16,000 veterans are diagnosed with prostate cancer each year

When detected early, prostate cancer is treatable.

143 hospitals in the VA system have the capability to diagnose and treat prostate cancer (and more may be available in your CCN)

90% of patients diagnosed with prostate cancer in the VA system are considered localized, non-metastatic and caught early

Exosome Diagnostics is proud to partner with Veterans Prostate Cancer Awareness and ZERO – The End of Prostate Cancer to support every Veteran with information and education addressing early detection of prostate cancer.

“I’m 61 and my PSA stays between 6 – 6.5ng/mL. I’ve always had a normal DRE. I discussed the pros and cons of getting a biopsy with my doctor, and then learned about the ExoDx test. We decided to get the test. My result came back below the cut-point at 10.67, and now he doesn’t want to see me for six months! Thank you for your test!”

Now available to Veterans

The ExoDx Prostate test is covered under the General Services Administration (GSA) award contract with Exosome Diagnostics. The ExoDx™ Prostate Test (EPI) will be available to 9 million additional men and 140 government entities including the VA Healthcare System, military branches such as Army, Navy, Air Force and Marines, as well as the U.S. Senate, House of Representatives and other legislative bodies.

If you have trouble getting access to the test, please call us at 844-396-7663, Option 3, then Option 2. We can help.

We’ve got you covered.

The ExoDx Prostate Test is covered by Medicare as well as the VA Healthcare system, Medicaid, and several private insurance plans. We can help you navigate the complexities of health insurance to determine if your plan covers the cost of the test.

References:

www.cancer.org/cancer/prostate-cancer/about/key-statistics.html
www.zerocancer.org/learn/about-prostate-cancer/facts-statistics/
www.cancer.va.gov/CANCER/pcf.asp
This test was evaluated and its performance characteristics determined by Exosome Diagnostics, Inc. Exosome Diagnostics is certified under the Clinical Laboratory Improvement Amendments (CLIA) Act of 1988 as qualified to perform high complexity clinical testing. CLIA number: 22D2093470.
Exosome Diagnostics and ExoDx are registered U.S. trademarks of Exosome Diagnostics, Inc.